Balyasny Asset Management
MRTX

Balyasny Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Balyasny Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,000
Closed -$1.06M – 3260
2023
Q4 		$1.06M Buy
+18,000
New +$1.01M ﹤0.01% 1667

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's MRTX Position: Q1 2024 in Review

Balyasny Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 19,921 shares — an estimated $1.17M sold.

Balyasny Asset Management first reported a position in MRTX in Q1 2015 and held it in 12 quarters. The position peaked at $33.8M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Balyasny Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 19,921 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.17M.
  • Balyasny Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
  • Balyasny Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $33.8M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.